Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intramuscular antipsychotics for agitation in psychiatric emergencies
ACTRN12610000033044Phase 4Completed
- Sponsor
- Federal University of Tocantins
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of olanzapine, ziprasidone, haloperidol, promethazine and midazolam in Schizophrenia Spectrum Disorders (SSD) and bipolar disorder (BD) (5 arms), sponsored by Federal University of Tocantins. Primary endpoints: Overt Agitation Severity Scale at 12 hours, Overt Aggression Scale at 12 hours and 1 more. Started Jan 2010; status: completed.
02
Drugs
olanzapineziprasidonehaloperidolpromethazinemidazolam
03
Conditions
Schizophrenia Spectrum Disorders (SSD)bipolar disorder (BD)
Beyond the preview
Go deeper on ACTRN12610000033044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000033044.